Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralymphatic Salsola kali allergen immunotherapy for allergic rhinitis
IRCT20161206031256N2Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Avanz Salsola kali in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Allergic rhinitis symptom, Quality of life and 2 more. Started Apr 2017; status: completed.
02
Drugs
Avanz Salsola kali
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on IRCT20161206031256N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20161206031256N2.